Effect of risk factors for acneiform rash induced by anti-epidermal growth factor receptor antibody drugs on survival: a retrospective observational study

Table 2 Patient characteristics for each group classified based on body weight

	Before propensity score matching
Characteristic	Low body weight < 67.2 kg (n = 53)	High body weight ≥ 67.2 kg (n = 14)	p-value	Low body weight < 67.2 kg (n = 14)	High body weight ≥ 67.2 kg (n = 14)	p-value
Sex (male/female)	25/28	12/2	0.010^a*	9/5	12/2	0.385^c
Age (years)	62.9 ± 1.50	61.3 ± 3.57	0.652^b	61.7 ± 4.02	61.3 ± 3.57	0.937^b
Anti-EGFR antibody drug (Cetuximab/Panitumumab)	15/38	3/11	0.743^c	4/10	3/11	1.000^c
Cancer stage (III/IV)	9/44	1/13	0.675^c	2/12	1/13	1.000^c
Height (cm)	162.0 ± 0.98	168.7 ± 2.58	0.005^b*	165.5 ± 1.21	168.7 ± 2.58	0.267^b
AST (IU/L)	28.2 ± 2.77	33.4 ± 9.20	0.468^b	31.5 ± 7.07	33.4 ± 9.20	0.874^b
ALT (IU/L)	22.9 ± 3.17	24.8 ± 2.76	0.762^b	22.6 ± 2.79	24.8 ± 2.76	0.590^b
T-Bil (mg/dL)	0.53 ± 0.05	0.50 ± 0.04	0.782^b	0.44 ± 0.04	0.50 ± 0.04	0.318^b
Scr (mg/dL)	0.74 ± 0.03	0.86 ± 0.06	0.098^b	0.85 ± 0.05	0.86 ± 0.06	0.822^b
Dosage of moisturizer for 1 month after initiation (g)	176.6 ± 13.6	167.9 ± 28.2	0.772^b	144.6 ± 13.9	167.9 ± 28.2	0.469^b
Minocycline treatment (Absence/Presence)	23/30	7/7	0.659^a	5/9	7/7	0.445^a

Values are presented as mean ± standard error
AST aspartate aminotransferase, ALT alanine aminotransferase, T-Bil total bilirubin, Scr serum creatinine
^achi-squared test
^bStudent’s t-test
^cFisher’s exact test
^*p < 0.05

ISSN: 2055-0294